Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Stopped Study not feasible
Conditions
- Chronic Lymphocytic Leukemia
- Loss of Chromosome 17p
Interventions
- DRUG: Ibrutinib
- DRUG: Venetoclax
Sponsor
Kerry Rogers
Collaborators